Table 3

Cellular markers of bone remodeling and bone pathology scores in patients with PsA

Median (range)

XR erosion score

XR narrowing score

Combined XR score

Number of joints with pencil-in-cup deformities on XR

Number of joints with new bone formation on XR

Total hip BMD T score

Percentage CD11b⁺/CD14⁺ cells (% all PBMCs)

3.3 (0.04-9.0)

0.35^a

0.36^a

0.38^a

0.11

0.03

-0.20

TRAP⁺ MNCs (per 10⁶ PBMCs)^c

29 (0-913)

0.31

0.41^a

0.37^a

0.34^a

0.00

-0.18

TRAP⁺ MNCs adjusted for number of CD11b⁺/CD14⁺ cells^c

9 (0-454)

0.18

0.21

0.17

0.28

0.00

-0.10

Number of pits (per 10⁶ PBMCs)

0 (0-500)

0.43^a

0.48^b

0.46^b

0.41^a

0.00

-0.33

Number of pits adjusted for number of CD11b⁺/CD14⁺ cells^c

0 (0-371)

0.45^b

0.49^b

0.47^b

0.45^b

0.01

-0.30

^aP < 0.05; ^bP < 0.01; ^cafter culture with RANKL and M-CSF. Spearman r values for correlations between cellular markers and measures of bone pathology. BMD, bone mineral density; M-CSF, macrophage-colony stimulating factor; MNCs, multinucleated cells; PBMCs, peripheral blood mononuclear cells; RANKL, receptor activator of nuclear factor-κB ligand; TRAP, tartrate-resistant acid phosphatise; XR, x-ray.

Dalbeth et al. Arthritis Research & Therapy 2010 12:R164   doi:10.1186/ar3123